Clinical trials: Coagulation Defect, open to volunteers
Postpartum Hemorrhage, Coagulation Disorder
SWIFT - SWIss Factor XIII Trial in PPH
The goal of this trial is to determine if postpartum blood loss can be reduced by replenishing coagulation factor XIII (FXIII) at an early stage of postpartum hemorrhage (PPH).
- Conditions
- Postpartum Hemorrhage, Coagulation Disorder, Coagulation Factor Deficiency, Hemorrhage
- Trial name
- SWIFT (NCT06481995)
- Testing
- Fibrogammin
- Where
- 9 sites in Switzerland
- Volunteers
- 988 people
- Sponsor
- Christian Haslinger
Primary Immune Thrombocytopenia (ITP)
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
The main purpose of this study is to look at the effect (efficacy) and safety of efgartigimod IV in participants with primary immune thrombocytopenia (ITP).
- Trial name
- advance NEXT (NCT06544499)
- Testing
- Efgartigimod IV
- Where
- 94 sites in United States, Austria and 15 more
- Volunteers
- 69 people
- Sponsor
- argenx
Immune Thrombocytopenia, System; Lupus Erythematosus
The Value of Interleukin-1β and Interleukin-33 Genetic Expression in the Pathogenesis and Differentiation of Primary ITP and SLE-Related Thrombocytopenia
Primary immune thrombocytopenia (ITP) is an autoimmune- mediated acquired bleeding disorder, defined as a platelet count less than 100×109/L without other causes of isolated thrombocytopenia.
- Trial name
- NCT07298733
- Testing
- measuring gene expression
- Volunteers
- 300 people
- Sponsor
- Sohag University
Endocarditis, Coagulation Disorder
The ENDOCARDITIS AUMC Data Collection
The investigators will compare patients with and without infective ndocarditis undergoing valve surgery and evaluate factors that may help optimise perioperative care of these high-risk patients.
- Conditions
- Endocarditis, Coagulation Disorder, Valve Disease, Heart
- Trial name
- ENDO_AUMC (NCT05139589)
- Testing
- None, observational
- Where
- Netherlands
- Volunteers
- 3,000 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Immune Thrombocytopenia, Treatment
Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia
To evaluate the safety and efficacy of avatrombopag in the treatment of pediatric primary immune thrombocytopenia in patients who have been treated with eltrombopag before and switched to avatrobopag because of poor efficacy…
- Trial name
- NCT06281327
- Testing
- Avatrombopag
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Severe Combined Immunodeficiency (SCID), Immunodeficiency With Predominant T-cell Defect, Unspecified
Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases
The purpose of this study is to determine whether bilateral orthotopic lung transplantation (BOLT) followed by cadaveric partially-matched hematopoietic stem cell transplantation (HSCT) is safe and effective for patients aged…
- Conditions
- Severe Combined Immunodeficiency (SCID), Immunodeficiency With Predominant T-cell Defect, Unspecified, Severe Chronic Neutropenia, Chronic Granulomatous Disease (CGD)
- Trial name
- BOLT+BMT (NCT01852370)
- Testing
- CD3/CD19 negative allogeneic hematopoietic stem cells
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Paul Szabolcs
Hemophilia A, Factor VIII (FVIII)
TG-INSIGHT With Joint POCUS, Hemostatic Potential in Patients With Severe Hemophilia A on Novel Replacement and Substitution FVIII Therapies
This is an observational research study to find out if there is a difference in the way children with moderate or severe hemophilia A, treated on two different types of factor replacement, form a clot and also evaluate if they…
- Trial name
- NCT07692217
- Testing
- Half-life factor VIII based replacement therapy, Non-FVIII based replacement therapy
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Texas Southwestern Medical Center
Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB)
HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB
The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacodynamics (PD) of multiple doses of ALN-6400 in adult and adolescent patients with VWD and HMB
- Trial name
- HMBeacon (NCT07575308)
- Testing
- ALN-6400
- Where
- 21 sites in United States, Netherlands and 3 more
- Volunteers
- 24 people
- Sponsor
- Alnylam Pharmaceuticals
Primary Immune Thrombocytopenia
A Study of Patients' Preferences for Primary Immune Thrombocytopenia Treatment
This study aims to evaluate treatment preferences of patients with Primary Immune Thrombocytopenia (ITP) in the United States (US) by conducting a preference elicitation survey.
- Trial name
- NCT07786077
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Purpura, Thrombocytopenic
Spanish-Portuguese Thrombotic Thrombocytopenic Purpura Registry
REPTT is an observational, prospective, multi-country, multicentre and non-interventional registry in which at least 300 patients with Thrombotic thrombocytopenic purpura (TTP) in Spain and Portugal will be evaluated.
- Trial name
- RE-PTT (NCT05914441)
- Testing
- Standard clinical practice
- Where
- 7 sites in Spain
- Volunteers
- 300 people
- Sponsor
- Fundación Española de Hematología y Hemoterapía
Primary Immune Thrombocytopenia (ITP)
A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids.
The purpose of this study is to assess the efficacy, safety and pharmacokinetics (PK) of ianalumab (VAY736) in addition to eltrombopag treatment; and to inform the dose of ianalumab in pediatric patients (5 to <18 years of age)…
- Trial name
- VAYHIT-P (NCT07660172)
- Testing
- Ianalumab, Eltrombopag
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Primary Immune Thrombocytopenia (ITP)
An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia
It is a clinical trial of a medicinal product Human Immunoglobulin for Intravenous Injection (5%) manufactured by Grand Shuyang Life Sciences (Chengdu) Co., Ltd. (hereinafter referred to as 5% IVIG).
- Trial name
- NCT07233213
- Testing
- Human immunoglobulin (pH4) for intravenous injection
- Where
- 9 sites in Turkey (Türkiye)
- Volunteers
- 36 people
- Sponsor
- Grand Shuyang Life Sciences (Chengdu) Co., Ltd.
Myeloproliferative Neoplasms
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in…
- Trial name
- NCT07441694
- Testing
- INCA036978, Standard disease-directed therapy
- Where
- 54 sites in United States, Australia and 9 more
- Volunteers
- 218 people
- Sponsor
- Incyte Corporation
Anemia, Coagulopathy
Patient Blood Management Implementation in CEE Study
The goal of the study is data collection on available fixed and personal assets required for Patient Blood Management (elements of the 3 pillars of PBM) in Central Eastern Europe countries hospitals, status before and after PBM…
- Trial name
- CEEPBM (NCT06878105)
- Testing
- Data collection on interventions performs as per medical routine
- Where
- Hungary
- Volunteers
- 2,000 people
- Sponsor
- Semmelweis University
Thrombotic Thrombocytopenic Purpura (TTP)
A Study in Children and, Adults With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated With Adzynma
Congenital thrombotic thrombocytopenic purpura (cTTP) is a rare blood disorder that some people are born with. It is caused by a problem in a gene passed down from parents to children, which affects the body's ability to produce…
- Trial name
- NCT07353099
- Testing
- No Intervention
- Where
- 7 sites in Austria, Germany
- Volunteers
- 50 people
- Sponsor
- Takeda
Trauma Induced Coagulopathy, Trauma Coagulopathy
Point of Care Fibrinogen Measurement in Trauma Patients in the Emergency Department
Background: Why This Study Matters When someone suffers a severe injury (like from a car crash), they can bleed heavily. One complication doctors often face is something called Trauma-Induced Coagulopathy (TIC).
- Conditions
- Trauma Induced Coagulopathy, Trauma Coagulopathy, Fibrinogen Deficiency, Fibrinogen; Deficiency, Acquired
- Trial name
- POCFIB (NCT07097337)
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Erasmus Medical Center
Cancer-related Stroke, Paraneoplastic Coagulopathy
Discovery of New Cancer in the 1-year Follow-up After Ischemic Stroke in Patients at Risk: The INVISIBLE-1 Study
INVISIBLE-1 aims to prospectively follow patients up to one year after ischemic stroke to: 1. Determine the cumulative incidence of occult cancer in patients with embolic stroke of undetermined source (ESUS) and elevated D-dimer…
- Conditions
- Cancer-related Stroke, Paraneoplastic Coagulopathy, Occult Cancer, Ischemic Stroke
- Trial name
- INVISIBLE-1 (NCT06100718)
- Where
- 3 sites in Switzerland
- Volunteers
- 370 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Post-Acute Sequelae of SARS-CoV-2 Infection, Long COVID
Observational Study of Intranasal IVIG in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patients Undergoing Medical Tourism
This observational study is being conducted by Healing Hope International to collect real-world data on an emerging treatment approach for Long COVID in patients with immunodeficiency.
- Conditions
- Post-Acute Sequelae of SARS-CoV-2 Infection, Long COVID, Long COVID Fatigue, Long COVID Syndrome
- Trial name
- IVIG-LC (NCT06992401)
- Volunteers
- 50 people
- Sponsor
- Tamara C Tamas
Hemophilia A, Severe
An Open-label Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of SKP-0141 for the Treatment and Prophylaxis in Severe Hemophilia a Patients
This is a prospective, multicenter, open-label study to assess efficacy, safety, pharmacokinetics (PK), and immunogenicity of human plasma-derived Factor VIII (FVIII) in previously treated patients (PTPs) with severe hemophilia…
- Trial name
- NCT06738901
- Testing
- SKP-0141
- Volunteers
- 55 people
- Sponsor
- SK Plasma Co., Ltd.
Hemophilia
The World Federation of Hemophilia Gene Therapy Registry
The aim of the WFH GTR is to provide a database in which long-term data on PWH who receive gene therapy from around the world, will be collected and housed.
- Trial name
- WFH GTR (NCT04883710)
- Testing
- Gene therapy
- Volunteers
- 5,000 people
- Sponsor
- World Federation of Hemophilia